Creative Planning’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$46M Buy
233,193
+51,403
+28% +$9.91M 0.03% 232
2025
Q4
$33.4M Buy
181,790
+25,644
+16% +$4.5M 0.02% 268
2025
Q3
$24M Buy
156,146
+23,151
+17% +$3.5M 0.02% 316
2025
Q2
$18.6M Sell
132,995
-12,849
-9% -$1.8M 0.02% 355
2025
Q1
$21.4M Buy
145,844
+23,464
+19% +$3.39M 0.02% 309
2024
Q4
$16M Buy
122,380
+10,004
+9% +$1.4M 0.02% 337
2024
Q3
$17.5M Buy
112,376
+8,346
+8% +$1.35M 0.02% 310
2024
Q2
$16.2M Buy
104,030
+16,066
+18% +$2.42M 0.02% 303
2024
Q1
$11.9M Buy
87,964
+14,529
+20% +$1.92M 0.01% 366
2023
Q4
$9.89M Sell
73,435
-10,898
-13% -$1.42M 0.02% 378
2023
Q3
$11.4M Buy
84,333
+6,595
+8% +$901K 0.02% 330
2023
Q2
$11.1M Buy
77,738
+10,086
+15% +$1.48M 0.01% 325
2023
Q1
$9.39M Buy
67,652
+2,160
+3% +$291K 0.01% 354
2022
Q4
$8.88M Buy
65,492
+8,797
+16% +$1.1M 0.01% 355
2022
Q3
$6.22M Buy
56,695
+6,146
+12% +$780K 0.01% 397
2022
Q2
$6.68M Buy
50,549
+225
+0.4% +$29.5K 0.01% 393
2022
Q1
$6.68M Buy
50,324
+16,905
+51% +$2.03M 0.01% 387
2021
Q4
$3.89M Sell
33,419
-745
-2% -$87.7K 0.01% 484
2021
Q3
$4.1M Buy
34,164
+5,794
+20% +$674K 0.01% 462
2021
Q2
$3.4M Sell
28,370
-4,671
-14% -$512K 0.01% 505
2021
Q1
$3.29M Sell
33,041
-891
-3% -$89.6K 0.01% 532
2020
Q4
$3.39M Buy
33,932
+1,491
+5% +$158K 0.01% 479
2020
Q3
$3.56M Buy
32,441
+2,441
+8% +$271K 0.01% 385
2020
Q2
$3.17M Buy
30,000
+5,356
+22% +$553K 0.01% 369
2020
Q1
$2.2M Buy
24,644
+2,125
+9% +$200K 0.01% 401
2019
Q4
$2.25M Buy
22,519
+1,845
+9% +$174K 0.01% 479
2019
Q3
$1.84M Sell
20,674
-704
-3% -$61K 0.01% 517
2019
Q2
$1.76M Buy
21,378
+40
+0.2% +$3.14K 0.01% 543
2019
Q1
$1.73M Sell
21,338
-1,482
-6% -$117K 0.01% 513
2018
Q4
$1.73M Buy
22,820
+2,179
+11% +$170K 0.01% 455
2018
Q3
$1.63M Buy
20,641
+2,579
+14% +$195K 0.01% 540
2018
Q2
$1.27M Sell
18,062
-233
-1% -$16.8K 0.01% 622
2018
Q1
$1.28M Buy
18,295
+88
+0.5% +$6.1K 0.01% 606
2017
Q4
$1.26M Sell
18,207
-74
-0.4% -$4.99K 0.01% 610
2017
Q3
$1.24M Sell
18,281
-3,985
-18% -$252K 0.01% 620
2017
Q2
$1.52M Sell
22,266
-395
-2% -$25.8K 0.01% 525
2017
Q1
$1.41M Buy
22,661
+2,020
+10% +$118K 0.01% 547
2016
Q4
$1.13M Buy
20,641
+2,350
+13% +$133K 0.01% 581
2016
Q3
$1.2M Buy
18,291
+4,177
+30% +$273K 0.01% 534
2016
Q2
$852K Buy
14,114
+7,534
+114% +$438K 0.01% 564
2016
Q1
$371K Sell
6,580
-83
-1% -$4.99K ﹤0.01% 880
2015
Q4
$452K Sell
6,663
-531
-7% -$34.8K ﹤0.01% 813
2015
Q3
$458K Buy
+7,194
New +$473K ﹤0.01% 774
2015
Q2
Sell
-5,287
Closed -$362K 1252
2015
Q1
$362K Sell
5,287
-181
-3% -$12.6K ﹤0.01% 892
2014
Q4
$385K Buy
5,468
+147
+3% +$10.5K ﹤0.01% 802
2014
Q3
$380K Buy
5,321
+567
+12% +$41.5K ﹤0.01% 765
2014
Q2
$353K Buy
4,754
+159
+3% +$11.5K ﹤0.01% 777
2014
Q1
$298K Sell
4,595
-1,329
-22% -$85.8K ﹤0.01% 822
2013
Q4
$352K Buy
5,924
+1,538
+35% +$83.5K 0.01% 631
2013
Q3
$228K Buy
4,386
+2,309
+111% +$116K ﹤0.01% 711
2013
Q2
$98K Buy
+2,077
New +$106K ﹤0.01% 1001

Other funds holding AZN

Creative Planning's AZN Position: Q1 2026 in Review

Creative Planning increased its AstraZeneca (AZN) stake by 28% in Q1 2026, buying an estimated $9.91M and bringing the position to 233,193 shares worth $46M. The position accounts for 0.03% of the portfolio, ranked #232.

Creative Planning first reported a position in AZN in Q2 2013 and has held it in 51 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Creative Planning held 233,193 shares of AstraZeneca worth $46M as of Q1 2026.
  • Creative Planning bought 51,403 AstraZeneca shares in Q1 2026, an estimated $9.91M.
  • AstraZeneca made up 0.03% of Creative Planning's portfolio in Q1 2026, its #232 holding.
  • Creative Planning first reported a position in AstraZeneca in Q2 2013 and has held it in 51 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.